A molecular mimic of phosphorylated prolactin (S179D PRL) secreted by eukaryotic cells has a conformation with an increased positive surface charge compared to that of unmodified prolactin (Biochemistry (2009) 48, (6887) DOI: 10.1021/bi9004864);A molecular mimic of phosphorylated prolactin (S179D PRL) secreted by eukaryotic cells has a conformation with an increased positive surface charge compared to that of unmodified prolactin

Biochemistry

Volumn 48, Issue 29, 2009, Pages 6887-6897

  Ueda, Eric K M ^a,b   Soares, Carlos R J ^a   Bartolini, Paolo ^a   DeGuzman, Ariel ^b   Lorenson, Mary Y ^b   Walker, Ameae M ^b  

^a INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CELL CULTURE; DIMERS; ESCHERICHIA COLI; LIGANDS; MAMMALS; MOLECULES;

ANTI-ANGIOGENIC ACTIVITY; CONFORMATIONAL CHANGE; INTRACELLULAR SIGNALING; MAMMALIAN CELL LINES; NEGATIVELY CHARGED; POSITIVE SURFACE CHARGE; SIGNALING MOLECULES; SIMPLE SUBSTITUTION;

CONFORMATIONS;

ASPARTIC ACID; HEPARIN; NICKEL; PROLACTIN; SERINE; SIGNAL PEPTIDE; ZINC;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BACTERIAL CELL; BINDING AFFINITY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ESCHERICHIA COLI; HYDROPHOBICITY; METAL BINDING; MOLECULAR MIMICRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; SURFACE CHARGE;

ESCHERICHIA COLI; EUKARYOTA; MAMMALIA;

EID: 67651210820     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi901399d     Document Type: Erratum

References (48)

1. Chen, T. J., Kuo, C. B., Tsai, K. F., Liu, J. W., Chen, D. Y., and Walker, A. M. (1998) Development of recombinant human prolactin receptor antagonists by molecular mimicry of the phosphorylated hormone. Endocrinology 139, 609-616.
2. Schroeder, M. D., Brockman, J. L., Walker, A. M., and Schuler, L. A. (2003) Inhibition of prolactin (PRL)-induced proliferative signals in breast cancer cells by a molecular mimic of phosphorylated PRL, S179D PRL. Endocrinology 144, 5300-5307.
3. Wu, W., Ginsburg, E., Vonderhaar, B. K., and Walker, A. M. (2005) S179D prolactin increases vitamin D receptor and p21 through upregulation of short 1b prolactin receptor in human prostate cancer cells. Cancer Res. 65, 7509-7515.
4. Xu, X., Kreye, E., Kuo, C. B., and Walker, A. M. (2001) A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when DU145 human prostate cancer cells were grown in nude mice. Cancer Res. 61, 6098-6114.
5. Ueda, E., Ozerdem, U., Chen,Y. H., Yao, M., Huang, K. T., Sun, H., Martins-Green, M., Bartolini, P., and Walker, A. M. (2006) A molecular mimic demonstrates that phosphorylated human prolactin is a potent anti-angiogenic hormone. Endocr. Relat. Cancer 13, 95-111.
6. Ueda, E. K., Lo, H. L., Bartolini, P., and Walker, A. M. (2006) S179D prolactin primarily uses the extrinsic pathway and mitogen-activated protein kinase signaling to induce apoptosis in human endothelial cells. Endocrinology 147, 4627-4637.
7. Walker, A. M. (2006) Therapeutic potential of S179D prolactin: From prostate cancer to angioproliferative disorders: The first selective prolactin receptor modulator. Expert Opin. Invest. Drugs 15, 1257-1267.
8. Walker, A. M. (2007) S179D Prolactin: Antagonistic Agony!. Mol. Cell. Endocrinol. 276, 1-9.
9. Trott, J. F., Hovey, R. C., Koduri, S., and Vonderhaar, B. K. (2004) Multiple new isoforms of the human prolactin receptor gene. Adv. Exp. Med. Biol. 554, 495-499.
10. Coss, D., Kuo, C.-Y. B., Yang, L., Ingleton, P., Luben, R., and Walker, A. M. (1999) Dissociation of Janus kinase 2 and signal transducer and activator of transcription 5 activation after treatment of Nb2 cells with a molecular mimic of phosphorylated prolactin. Endocrinology 140, 5087-5094.
11. Tan, D., Johnson, D. A., Wu, W., Zeng, L., Chen, Y. H., Chen,W. Y., Vonderhaar, B. K., and Walker, A. M. (2005) Unmodified prolactin (PRL) and S179D PRL-initiated bioluminescence resonance energy transfer between homo- and hetero-pairs of long and short human PRL receptors in living human cells. Mol. Endocrinol. 19, 1291-1303.
12. Wu, W., Chen, Y. H., Ueda, E., Tan, D., Bartolini, P., and Walker, A. M. (2006) Different forms of prolactin have opposing effects on the expression of cell cycle regulatory proteins in differentiated mammary epithelial cells. Oncol. Res. 16, 75-84.
13. Wu, W., Coss, D., Lorenson,M. Y., Kuo, C. B., Xu, X., and Walker, A. M. (2003) Different biological effects of unmodified prolactin and a molecular mimic of phosphorylated prolactin involve different signaling pathways. Biochemistry 42, 7561-7570.
14. Soares, C. R., Glezer, A., Okazaki, K., Ueda, E. K., Heller, S. R., Walker, A. M., Goffin, V., and Bartolini, P. (2006) Physico-chemical and biological characterizations of two human prolactin analogs exhibiting controversial bioactivity, synthesized in Chinese hamster ovary (CHO) cells. Protein Expression Purif. 48, 182-194.
15. Ellgaard, L., and Helenius, A. (2003) Quality control in the endoplasmic reticulum. Nat. Rev. Mol. Cell Biol. 4, 181-191.
16. Ueda, E. K., Gout, P. W., and Morganti, L. (2001) Ni(II)-based immobilized metal ion affinity chromatography of recombinant human prolactin from periplasmic Escherichia coli extracts. J. Chromatogr., A 922, 165-175.
17. Soares, C. R., Gomide, F. I., Ueda, E. K., and Bartolini, P. (2003) Periplasmic expression of human growth hormone via plasmid vectors containing the lambda PL promoter: Use of HPLC for product quantification. Protein Eng. 16, 1131-1138.
18. Soares, C. R., Morganti, L., Miloux, B., Lupker, J. H., Ferrara, P., and Bartolini, P. (2000) High-level synthesis of human prolactin in Chinese hamster ovary cells. Biotechnol. Appl. Biochem. 32, 127-135.
19. Sambrook, J., and Russel, D. W. (2001) Molecular Cloning: A Laboratory Manual , 3rd ed., Cold Spring Harbor Laboratory Press, Plainview, NY.
20. Morganti, L., Soares, C. R., Affonso, R., Gout, P. W., and Bartolini, P. (1998) Synthesis and characterization of recombinant, authentic human prolactin secreted into the periplasmic space of Escherichia coli. Biotechnol. Appl. Biochem. 27 (Part 1), 63-70.
21. Soares, C. R., Camargo, I. M., Morganti, L., Gimbo, E., Oliveira, J. E., Legoux, R., Ferrara, P., and Bartolini, P. (2002) Reversed-phase high-performance liquid chromatography method for the determination of prolactin in bacterial extracts and in its purified form. J. Chromatogr., A 955, 229-236.
22. Andrade, M. A., Chacon, P., Merelo, J. J., and Moran, F. (1993) Evaluation of secondary structure of proteins from UV circular dichroism spectra using an unsupervised learning neural network. Protein Eng. 6, 383-390.
23. Lambert, C., Léonard, N., De Bolle, X., and Depiereux, E. (2002) ESyPred3D: Prediction of proteins 3D structures. Bioinformatics 18, 1250-1256.
24. Teilum, K., Hoch, J. C., Goffin, V., Kinet, S., Martial, J. A., and Kragelund, B. B. (2005) Solution structure of human prolactin. J. Mol. Biol. 351, 810-823.
25. Khurana, S., Kuns, R., and Ben-Jonathan, N. (1999) Heparin-binding property of human prolactin: A novel aspect of prolactin biology. Endocrinology 140, 1026-1029.
26. Nagradova, N. (2007) Enzymes catalyzing protein folding and their cellular functions. Curr. Protein Pept. Sci. 8, 273-282.
27. Makrides, S. C. (1996) Strategies for achieving high-level expression of genes in Escherichia coli. Microbiol. Rev. 60, 512-538.
28. Intasai, N., Arooncharus, P., Kasinrerk, W., and Tayapiwatana, C. (2003) Construction of high-density display of CD147 ectodomain on VCSM13 phage via gpVIII: Effects of temperature, IPTG, and helper phage infection period. Protein Expression Purif. 32, 323-331.
29. Bessette, P. H., Aslund, F., Beckwith, J., and Georgiou, G. (1999) Efficient folding of proteins with multiple disulfide bonds in the Escherichia coli cytoplasm. Proc. Natl. Acad. Sci. U.S.A. 96, 13703-13708.
30. Soares, C. R., Ueda, E. K., Oliveira, T. L., Gomide, F. I., Heller, S. R., and Bartolini, P. (2008) Distinct human prolactin (hPRL) and growth hormone (hGH) behavior under bacteriophage lambda PL promoter control: Temperature plays a major role in protein yields. J. Biotechnol. 133, 27-35.
31. Piwnica, D., Touraine, P., Struman, I., Tabruyn, S., Bolbach, G., Clapp, C., Martial, J. A., Kelly, P. A., and Goffin, V. (2004) Cathepsin D processes human prolactin into multiple 16K-like N-terminal fragments: Study of their antiangiogenic properties and physiological relevance. Mol. Endocrinol. 18, 2522-2542.
32. Anelli, T., and Sitia, R. (2008) Protein quality control in the early secretory pathway. EMBO J. 27, 315-327.
33. Greenan, J. R., Balden, E., Ho, T. W. C., and Walker, A. M. (1989) Biosynthesis of the secreted 24 kd isoforms of prolactin. Endocrinology 125, 2041-2048.
34. Wicks, J. R., and Brooks, C. L. (1999) Prolactin kinase activity in bovine anterior pituitary sub-cellular fractions. Mol. Cell. Endocrinol. 147, 125-132.
35. Langenheim, J. F., Tan, D., Walker, A. M., and Chen, W. (2006) Two wrongs can make a right: Dimers of prolactin and growth hormone receptor antagonists behave as agonists. Mol. Endocrinol. 20, 661-674.
36. Bogorad, R. L., Courtillot, C., Mestayer, C., Bernichtein, S., Harutyunyan, L., Jomain, J. B., Bachelot, A., Kuttenn, F., Kelly, P. A., Goffin, V., and Touraine, P. (2008) Identification of a gainof-function mutation of the prolactin receptor in women with benign breast tumors. Proc. Natl. Acad. Sci. U.S.A. 105, 14533-14538.
37. Rowlinson, S. W., Yoshizato, H., Barclay, J. L., Brooks, A. J., Behncken, S. N., Kerr, L. M., Millard, K., Palethorpe, K., Nielsen, K., Clyde-Smith, J., Hancock, J. F., and Waters, M. J. (2008) An agonist-induced conformational change in the growth hormone receptor determines the choice of signalling pathway. Nat. Cell Biol. 10 (6), 740-747.
38. Seubert, N., Royer, Y., Staerk, J., Kubatzky, K. F., Moucadel, V., Krishnakumar, S., Smith, S. O., and Constantinescu, S. N. (2003) Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol. Cell 12, 1239-1250.
39. Svensson, L. A., Bondensgaard, K., Noørskov-Lauritsen, L., Christensen, L., Becker, P., Andersen, M. D., Maltesen, M. J., Rand, K. D., and Breinholt, J. (2008) Crystal structure of a prolactin receptor antagonist bound to the extracellular domain of the prolactin receptor. J. Biol. Chem. 283, 19085-19094.
40. Presta, M., Dell'Era, P., Mitola, S., Moroni, E., Ronca, R., and Rusnati, M. (2005) Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 16, 159-178.
41. Kuo, C. B., Wu, W., Xu, X., Yang, L., Chen, C., Coss, D., Birdsall, B., Nasseri, D., and Walker, A. M. (2002) Pseudophosphorylated prolactin (S179D PRL) inhibits growth and promotes β-casein gene expression in the rat mammary gland. Cell Tissue Res. 309, 429-437.
42. Naylor, M. J., Oakes, S. R., Gardiner-Garden, M., Harris, J., Blazek, K., Ho, T. W. C., Li, F. C., Wynick, D., Walker, A. M., and Ormandy, C. J. (2005) Transcriptional changes underlying the secretory activation phase of mammary gland development. Mol. Endocrinol. 19, 1868-1883.
43. Fink,A. L., Calciano, L. J., Goto, Y., Kurotsu, T., and Palleros, D. R. (1994) Classification of acid denaturation of proteins: Intermediates and unfolded states. Biochemistry 33, 12504-12511.
44. Jennings, P. A., and Wright, P. E. (1993) Formation of a molten globule intermediate early in the kinetic folding pathway of apomyoglobin. Science 262, 892-896.
45. Englander, S. W. (2000) Protein folding intermediates and pathways studied by hydrogen exchange. Annu. Rev. Biophys. Biomol. Struct. 29, 213-238.
46. Folkman, J. (2006) Antiangiogenesis in cancer therapy: Endostatin and its mechanisms of action. Exp. Cell Res. 312, 594-607.
47. Giladi, H., Goldenberg, D., Koby, S., and Oppenheim, A. B. (1995) Enhanced activity of the bacteriophage lambda PL promoter at low temperature. FEMS Microbiol. Rev. 17, 135-140.
48. Luck,D. N., Gout, P. W., Beer, C. T., and Smith, M. (1989) Bioactive recombinant methionyl bovine prolactin: Structure-function studies using site-specific mutagenesis. Mol. Endocrinol. 3, 822-831.